Sign Up
Stories
Advancements in Psychiatric Treatments
Share
Bristol Myers Strengthens Neuroscience P...
ABVC BioPharma's Patent and Partnership
ANJESO Drug Insight and Market Forecast
AlzeCure's Drug Therapy Focus
Overview
API
Biopharmaceutical companies Karuna Therapeutics and Newron Pharmaceuticals make significant progress in the treatment of psychiatric conditions, with Karuna submitting an NDA for its schizophrenia drug, KarXT, and Newron's evenamide showing promising results in a Phase II study for treatment-resistant schizophrenia. Both companies are preparing for Phase III trials and anticipate potential market success for their drugs.
Ask a question
How might the approval of KarXT impact the treatment landscape for schizophrenia and its associated negative symptoms?
How might the progress of Karuna Therapeutics and Newron Pharmaceuticals influence the development of other psychiatric treatments and the broader healthcare industry?
What are the potential implications of Newron Pharmaceuticals' evenamide showing significant symptom improvements in treatment-resistant schizophrenia on the current treatment landscape?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jun 2023
Jul 2023
Aug 2023
Sep 2023
Oct 2023
Coverage